Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3316531 Capsaicin-Induced Dermal Blood Flow Study
NCT03611608Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3316531 in psoriasis (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Capsaicin-Induced Dermal Blood Flow Following LY3316531 Compared to Placebo at Day 24. Started Aug 2018; status: completed.
02
Drugs
LY3316531
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03611608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611608.